May 2026

Week in Review: FDA confirms recall for vascular device | BATMAN to the rescue | Prasugrel after PCI | GLP-1 drugs & AFib ()
News Alert: FDA shares new warning about Impella heart pumps after death ()
Insulin pods recalled | Cardiology groups support bill | Treating ‘broken hearts’ | AI delivers answers | Prasugrel after PCI ()
AHA takes on cardiac amyloidosis | Have clinicians been wrong about PAD? | FDA OKs new AI for heart failure ()
The high costs of robotic tech | Medtronic recalls thousands of devices | TAVR in younger patients | FDA approves next-gen valve ()
Heart pump controllers recalled | Concomitant EP procedures for AFib | FDA's update after deaths | Pacing techniques & TAVR ()
The risks of PFA | FDA's warning after patient death | Cardiac ablations in ASCs | Group wants TAVR changes ()
How TAVR implant depth impacts outcomes | A closer look at GLP-1 drugs & AFib | BATMAN technique to the rescue ()
Week in Review: Reprocessed catheters recalled | New payment model almost here | 3-year SMART data | Hypertension drug approved ()
New payment model on the way | Major recalls could impact care | Policy changes for breakthrough devices ()
FDA warns public after patient death | Medtronic recalls heart devices | 'Compelling' new PE data | Pushing for TAVR changes ()
News Alert: Medtronic recalls thousands of surgical devices ()
New IVL tech overcomes previous limitations | 3-year SMART data looks at TAVR outcomes | Artivion acquires Endospan for $135M ()
FDA approves next-gen mitral valve | Doctors are first in world to use new TAVR technique | Preventing a common complication ()
Key updates in PFA & beyond | More good IVL news for Boston Scientific | FDA approves new hypertension drug ()
Cardiologists scramble to prepare for new policy | Boston Scientific invests $1.5B in TAVR developer | FDA clears cath lab tech ()
The latest on PFA risks | EP catheters recalled | Doctors exempt from work visa freeze | Good news for Heartflow ()
Top 10 most popular cardiology video interviews this past month ()
Week in Review: New IVL data | TAVR trend prompts 'call to action' | Compensation climbs | Ablations in ASCs | More recalls ()
News Alert: Thousands of reprocessed EP catheters recalled ()
New heart failure device impresses | Cardiac amyloidosis in the spotlight | Experts agree: HFmrEF should not be ignored ()
Cardiology salaries outpace other specialties | A new TAVR technique | Cardiac amyloidosis in the spotlight | BP drug recalled ()
A new device warning after 3 deaths | AI predicts stroke risk | FDA clears intravascular imaging tech | IV fluids recalled ()
Cardiac ablations in ASCs | Shockwave's new IVL catheter | Clopidogrel resistance | Sex dreams & the heart | AI for stroke risk ()
Heartflow sues AI rival Cleerly | Another win for opportunistic screening | Predicting TAVR outcomes | Key approvals for Abbott ()
Is TAVR too common among younger patients? | New-look heart failure device delivers | SCAI to study women in the cath lab ()
Cardiologist compensation keeps climbing | Investing in robotic tech | Doc agrees to pay $6.7M | Virtual nurses ()
ASNC speaks to policymakers | New IVL tech impresses | FDA clears high-pressure balloon catheter | RSNA names a new editor ()
Pacemakers recalled again | Johnson & Johnson makes a move | GLP-1 drugs & AFib | Strokes after PFA | New LAAO data ()
More recalls announced due to high-risk device | AATS helps surgeons manage a major complication | How guidelines impact care ()
Week in Review: TAVR or SAVR? | Key trends in cardiac CT | Fraud allegations lead to $6.7M settlement | CTO PCI ()
FDA clears intravascular imaging tech | Key trends in cardiac CT | Heartflow sues rival | Opportunistic screening ()
Vascular specialist agrees to pay $6.7M | Robotic heart surgery: Worth the cost? | E-cigarette concerns | Heart tech on display ()
FDA clears next-gen heart device | Catching up with SCAI's new president | A warning for cath labs | Late-breaking PCI data ()
New data confirm long-term durability of Resilia tissue | CCTA delivers clarity, better outcomes | Cannabis use & heart attacks ()
TAVR Highlights: Predicting long-term outcomes | SCAI, ACC & STS share a message | Weight loss drug linked to key benefits ()
TAVR or SAVR? A closer look at those decisions | New Impella 5.5 data | First patient enrolled in massive heart failure trial ()
Teen's death at center of new lawsuit | Surgery outperforms GLP-1 drugs | Long-term antidepressant use & SCD ()
AI helps 3D imaging labs evolve | Catheters recalled over safety risk | New ways to predict TAVR outcomes ()
Looking Back: Cardiologist fired for speaking out | Hospital sues practice | Strokes after PFA | Energy drinks & heart disease ()
Surgery outperforms GLP-1 drugs | CEPDs fail to make an impact | Redo TAVR: Supra-annular vs. intra-annular valves ()
Week in Review: FDA clears imaging platform | Vascular device linked to deaths | GLP-1 drugs & AFib | Pacemakers recalled again ()
Optimism about cardiology’s future | HRS leader looks ahead | Women live longer after TAVR | J&J announces acquisition ()